Is Global X Video Games & Esports ETF (HERO) a Buy, Sell, or Hold?
NASDAQ : HERO
Global X Video Games & Esports ETF — News
$24.4445 USD
$0.15 (0.64%)
- Volume
- 18.08K
- Average Volume
- 24.37K
- Market Capitalization
- $125.63M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $34.68
- Year Low
- $23.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
| Source | Headline |
|---|---|
|
Duke Energy supports South Carolina first responders with $500,000 in grants for emergency preparedness
Duke Energy supports South Carolina first responders with $500,000 in grants for emergency preparedness PR Newswire gurufocus.com - 2026-06-05 10:00:00 |
|
Duke Energy supports South Carolina first responders with $500,000 in grants for emergency preparedness
Funding goes to 34 nonprofits and government agencies across the Palmetto State Since 2022, Duke Energy's HERO Grant Program has funded 133 grants with $2.5 million, delivering critical support to nonprofits and local agencies GREENVILLE, S.C., June 5, 2026 /PRNewswire/ -- As emergency managers, first responders and community leaders are preparing their communities for the 2026 hurricane season, the Duke Energy Foundation is awarding $500,000 through the 2026 Helping Emergency Response Organizations (HERO) Grant Program to help South Carolina communities be prepared for the impacts from severe weather. prnewswire.com - 2026-06-05 09:13:00 |
|
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company's previously announced voluntary pause. The clinical hold applies to all ongoing clinical studies under the IND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS) and the Phase 3 open-label extension (OLE) trial (AVK-101-302). The Company remains in active discussions with the FDA to support resolution of the clinical hold and determine a path forward for the ARD-101 program. globenewswire.com - 2026-05-14 16:01:00 |
